Healthcare Industry News: Johnson and Johnson
News Release - June 26, 2014
Tris Pharma Expands R&D Team with addition of Chief Medical Officer and Vice President of Regulatory Affairs
MONMOUTH JUNCTION, N.J., June 26, 2014 -- (Healthcare Sales & Marketing Network) -- Tris Pharma, a specialty pharmaceutical company focused on developing innovative technology-based products announced two key additions to its' executive team: Sally A. Berry, MD, PhD will join as Chief Medical Officer and Norma Cappetti will join as Vice President of Regulatory Affairs.Dr. Berry is a Board Certified Psychiatrist with a distinguished career in Medical Affairs and Clinical Development of many leading products. Specifically, she has successfully contributed to the development of products such as Quillivant® XR, Invega®, Risperdal®, Risperdal Consta®, Concerta®, etc. and authored or co-authored over 20 publications. Prior to joining Tris, most recently she was working with Pfizer, and prior to that was Chief Medical Officer of NextWave Pharmaceuticals. Dr. Berry also held senior management positions at Johnson & Johnson (J&J) in medical and clinical development areas. Before J&J, she was in academia at Emory University and private practice as staff psychiatrist. She graduated with an MD and Ph.D. in Pharmacology from Case Western Reserve University; and an MS in Neurobiology and BS in Biology, both from Purdue University.
Ms. Cappetti joins Tris with over 35 years of experience in the pharmaceutical industry including 25 years in managing and leading Regulatory Affairs. Ms. Cappetti has both international and domestic regulatory experience and her therapeutic areas of experience include but are not limited to CNS, Respiratory, Cardiovascular and Endocrinology. She has successfully delivered strategic advice, NDA/ANDA submissions and operational excellence in her prior roles with Ono Pharma, Celltech Americas, Medeva Americas and Fisons Corporation.
"We are very pleased to welcome Sally and Norma to our management team," said Ketan Mehta, President and CEO. "Their experience within the medical/clinical and regulatory environments, as well as with the FDA, will be a tremendous asset to Tris as we continue to execute on our pipeline and partnered products."
About Tris Pharma
Tris Pharma is a specialty pharmaceutical company focused on the research and development of technologies-driven products. Tris has pioneered the delivery of sustained release in the liquid, chewable/ODT and strip dosage forms so patients do not have to swallow a pill. Tris' Nobuse™ technology provides abuse deterrence for opioids and other abuse-prone drugs. Tris' R&D and manufacturing facilities are located in Monmouth Junction, New Jersey, U.S.A. For more information, please visit http://www.trispharma.com.
Quillivant is a registered trademark of Pfizer, Inc. Invega, Risperidal, Risperidal Consta and Concerta are registered trademarks of Johnson and Johnson Corporation.
Source: Tris Pharma
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
